Small Molecules
10 October 2013
Relypsa Reports Positive Top-Line Results for the Second Part of Its Two-Part Pivotal Phase 3 Trial of Patiromer10 October 2013
Lundbeck and Otsuka Initiate Phase III Clinical Trials on Lu AE58054 as a New Add-on Treatment for Alzheimer’s Disease10 October 2013
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk-Benefit10 October 2013
Dynavax Initiates First Human Trial in Asthma Program10 October 2013
MIV-247 has been selected as a candidate drug and enters development for the treatment of neuropathic pain9 October 2013
Alkermes Announces Alignment with FDA on Plans for Pivotal Program for ALKS 5461 for Major Depressive Disorder9 October 2013
Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders9 October 2013
Qsymia Shown to Reduce Progression to Type 2 Diabetes in High-Risk Overweight or Obese Patients8 October 2013
Keryx Biopharmaceuticals Announces FDA Acceptance for Filing of Zerenex(TM) New Drug Application8 October 2013
Ligand Announces FDA Acceptance of Investigational New Drug Application for Glucagon Receptor Antagonist Program8 October 2013
Alkermes Announces Completion of Patient Enrollment in Pivotal Phase 3 Study of Aripiprazole Lauroxil4 October 2013
Puma Biotechnology Initiates Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients4 October 2013
ENDECE Neural’s NDC-1308 Potently Enhances Remyelination in Experimental Models of Multiple Sclerosis (MS)News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports